Suchergebnisse - "Famiglietti, V"

PubPharm (4)

1

Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA : Individual patient data pooled analysis of CRICKET and CAVE trials

enthalten in: Cancer medicine | 2023

von Martini, G. | Ciardiello, D. | Famiglietti, V. | +19

2

Cetuximab as third‐line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild‐type circulating tumor DNA : Individual patient data pooled analysis of CRICKET and CAVE trials

enthalten in: Cancer Medicine | 2023

von Martini, G. | Ciardiello, D. | Famiglietti, V. | +19

3

Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer : findings from a real-life multicenter Italian study (CRC-KR GOIM)

enthalten in: ESMO open | 2022

von Ciardiello, D. | Chiarazzo, C. | Famiglietti, V. | +31

4

Three dimensional primary cultures for selecting human breast cancers that are sensitive to the anti-tumor activity of ipatasertib or taselisib in combination with anti-microtubule cytotoxic drugs

enthalten in: Breast (Edinburgh, Scotland) | 2018

von Orditura, M. | Della Corte, C. | Diana, A. | +15

1
[1]